• bitcoinBitcoin(BTC)$83,427.00-1.22%
  • ethereumEthereum(ETH)$2,655.88-1.58%
  • tetherTether(USDT)$1.000.00%
  • binancecoinBNB(BNB)$771.49-0.09%
  • rippleXRP(XRP)$1.50-1.37%
  • usd-coinUSDC(USDC)$1.000.00%
  • solanaSolana(SOL)$120.19-0.70%
  • tronTRON(TRX)$0.3333420.14%
  • zcashZcash(ZEC)$1,568.13-4.77%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.06-0.38%
  • HyperliquidHyperliquid(HYPE)$90.07-3.39%
  • dogecoinDogecoin(DOGE)$0.094832-1.54%
  • chainlinkChainlink(LINK)$14.04-0.71%
  • moneroMonero(XMR)$542.67-3.35%
  • whitebitWhiteBIT Coin(WBT)$83.23-1.08%
  • USDSUSDS(USDS)$1.000.00%
  • cardanoCardano(ADA)$0.2526590.18%
  • RainRain(RAIN)$0.012556-1.78%
  • leo-tokenLEO Token(LEO)$9.04-0.04%
  • stellarStellar(XLM)$0.214205-0.32%
  • nearNEAR Protocol(NEAR)$5.243.43%
  • bitcoin-cashBitcoin Cash(BCH)$314.77-5.67%
  • uniswapUniswap(UNI)$9.36-3.93%
  • CantonCanton(CC)$0.1440505.67%
  • litecoinLitecoin(LTC)$70.90-0.88%
  • suiSui(SUI)$1.256.19%
  • Ethena USDeEthena USDe(USDE)$1.00-0.01%
  • avalanche-2Avalanche(AVAX)$10.820.48%
  • daiDai(DAI)$1.000.01%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.613.14%
  • USD1USD1(USD1)$1.000.00%
  • hedera-hashgraphHedera(HBAR)$0.0949191.45%
  • quant-networkQuant(QNT)$257.6850.53%
  • BittensorBittensor(TAO)$310.76-3.21%
  • BitwayBitway(BTW)$1.2621.45%
  • shiba-inuShiba Inu(SHIB)$0.000006-1.89%
  • Global DollarGlobal Dollar(USDG)$1.000.00%
  • crypto-com-chainCronos(CRO)$0.064542-3.13%
  • tether-goldTether Gold(XAUT)$4,206.16-1.72%
  • EthenaEthena(ENA)$0.2733942.14%
  • OndoOndo(ONDO)$0.575.95%
  • paypal-usdPayPal USD(PYUSD)$1.000.00%
  • MemeCoreMemeCore(M)$1.19-3.15%
  • okbOKB(OKB)$118.93-1.73%
  • Ripple USDRipple USD(RLUSD)$1.000.01%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • Pump.funPump.fun(PUMP)$0.00511916.26%
  • aaveAave(AAVE)$151.11-2.82%
  • BlackRock USD Institutional Digital Liquidity FundBlackRock USD Institutional Digital Liquidity Fund(BUIDL)$1.000.00%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.150.10%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

Costco to offer deep discounts on Ozempic, Wegovy

October 4, 2025
in Business
Reading Time: 3 mins read
A A
Costco to offer deep discounts on Ozempic, Wegovy
ShareShareShareShareShare

It might be time to dust off that Costco card. 

YOU MAY ALSO LIKE

Solidcore signs deal for Upper East Side location

Stephen Ross expanding in Boca Raton at a 124-acre, former IBM facility

The wholesale giant has partnered with Danish drugmaker Novo Nordisk to offer blockbuster weight-loss medications like Ozempic and Wegovy at deep discounts for members without insurance.

“Everyone deserves care that’s simple, reliable and within reach — and we’re proud to lead the way in helping make that a reality,” Dave Moore, executive vice president of Novo Nordisk’s US operations, told Fox Business. 

Costco members need a valid prescription in order to purchase the weight-loss medications. JHVEPhoto – stock.adobe.com

Starting Friday, Oct. 3rd, eligible members can grab a four-week supply of the injectable GLP-1s for $499 at more than 600 Costco pharmacies nationwide.

Costco Executive Members and Costco Citibank Visa cardholders can snag an extra 2% off their prescriptions, subject to applicable terms, a Novo Nordisk spokesperson told PEOPLE, subject to terms.

That’s notable, because many health plans don’t cover the pricey medications. Without insurance, a month’s supply runs about $1,000 for Ozempic and $1,350 for Wegovy, according to GoodRx.

To get in on the deal, shoppers need a valid prescription and must be enrolled in the Costco Member Prescription Program. For those with insurance, the price depends on their plan.

Ozempic and Wegovy are manufactured by Danish drugmaker Novo Nordisk. Fernanda – stock.adobe.com

Ozempic and Wegovy both pack the same powerful punch: semaglutide, an active ingredient that mimics a hormone in the body to curb appetite and control blood sugar.

Ozempic is FDA-approved to treat type 2 diabetes, while Wegovy is specifically approved for weight management in adults and children 12 and older with obesity.

Both medications can help people lose weight, but studies suggest Wegovy may be more effective because it is given at higher doses.

Early research also hints that semaglutide could offer additional benefits, such curtailing substance abuse and aiding in the treatment and prevention of Alzheimer’s disease.

But its not all smooth sailing. Patients have reported a wide-range of side effects while taking the drugs, with gastrointestinal issues like nausea, diarrhea and constipation among the most common.

Still, demand for GLP-1s has skyrocketed in recent years, leading to occasional shortages.

Those shortages — along with the drugs’ high price tags — have driven some consumers to seek counterfeit versions from compounded pharmacies, which come at a fraction of the cost.

Novo Nordisk and the FDA have pushed back on the practice, warning that the off-brand drugs haven’t been evaluated for safety or effectiveness.

“We want to make sure we offer the real and authentic Wegovy and Ozempic where patience seek care,” Moore told Today. “And we know that Costco is a trusted brand.”

Both Ozempic and Wegovy have become popular tools for weight loss in recent years. ISO101 – stock.adobe.com

Novo Nordisk already sells Ozempic and Wegovy for $499 through its direct-to-consumer website, and offers the same deal at CVS and Walmart,

Still, experts say even the reduced price tag may be too steep for many Americans.

“The people who have the greatest need for these medications are precisely the people who are in lower socioeconomic strata who have either poor insurance or no insurance, and don’t have the discretionary funds to be spending on medications,” Dr. Harlan Krumholz, cardiologist and professor of medicine at Yale School of Medicine, told NBC News.

“If we really want to make the biggest difference on the health of the nation, we have to make sure that the people who would benefit the most have access to medications that are being shown to be beneficial,” he added.

The push to make GLP-1 treatments more affordable comes as the US faces a growing crisis of the waistline.

More than two in five American adults are classified as obese, along with about one in five children and teens nationwide.

Carrying that extra weight can not only affect quality of life but also significantly raise the risk of chronic conditions like type 2 diabetes, high blood pressure, high cholesterol, heart disease and even certain cancers over time.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Solidcore signs deal for Upper East Side location
Business

Solidcore signs deal for Upper East Side location

September 27, 2026
Stephen Ross expanding in Boca Raton at a 124-acre, former IBM facility
Business

Stephen Ross expanding in Boca Raton at a 124-acre, former IBM facility

September 27, 2026
Times Square may score another Asian entertainment lease
Business

Times Square may score another Asian entertainment lease

September 27, 2026
Rob Bonta’s Paramount-WBD debacle has created political chaos
Business

Rob Bonta’s Paramount-WBD debacle has created political chaos

September 27, 2026
Next Post
Critics slam New York fashion week as ‘unmemorable’ during cautious time for economy

Critics slam New York fashion week as 'unmemorable' during cautious time for economy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
Disney legal chief warns of ‘hard choices’ as layoffs loom

Disney legal chief warns of ‘hard choices’ as layoffs loom

September 25, 2026
Cricut’s New DIY Machines Let You Print And Cut Your Own Stickers

Cricut’s New DIY Machines Let You Print And Cut Your Own Stickers

September 25, 2026
StepFun Launches Step 5 Preview: A 600B-Total, 27B-Active MoE Model With 1M Context for Long-Horizon Agentic Work

StepFun Launches Step 5 Preview: A 600B-Total, 27B-Active MoE Model With 1M Context for Long-Horizon Agentic Work

September 21, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!